よむ、つかう、まなぶ。
【参考資料３】【英版R4.1.17】Nippon AMR One Health Report (NAOR) 2020 (3 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_23261.html |
| 出典情報 | 国際的に脅威となる感染症対策関係閣僚会議 薬剤耐性ワンヘルス動向調査検討会（第9回 1／17）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
1) Surveys of attitudes among the public ........................................................................................................... 83
(2) Surveys of healthcare providers ...................................................................................................................... 84
1) Survey of attitudes among pharmacists at health insurance pharmacies ........................................................ 84
2) Survey of attitudes among undergraduate medical students .......................................................................... 85
(3) Survey of veterinary science students ............................................................................................................. 85
Way Forward ............................................................................................................................ 87
Appendix ................................................................................................................................................ 88
(1) Japan Nosocomial Infections Surveillance (JANIS) ....................................................................................... 88
1) Overview ....................................................................................................................................................... 88
2) Methods for submission................................................................................................................................. 88
3) Prospects ........................................................................................................................................................ 88
(2) National Epidemiological Surveillance of Infectious Disease (NESID) ......................................................... 89
1) Overview ....................................................................................................................................................... 89
2) Reporting criteria ........................................................................................................................................... 89
3) System ........................................................................................................................................................... 90
4) Prospects ........................................................................................................................................................ 90
(3) Japan Surveillance for Infection Prevention and Health‐care Epidemiology (J-SIPHE)................................. 91
1) Overview ....................................................................................................................................................... 91
2) System ........................................................................................................................................................... 91
3) Prospects ........................................................................................................................................................ 91
(4) Trend surveillance of antimicrobial-resistant Mycobacterium tuberculosis .................................................... 91
1) Overview ....................................................................................................................................................... 91
2) Survey methods ............................................................................................................................................. 91
3) System ........................................................................................................................................................... 91
4) Prospects ........................................................................................................................................................ 91
(5) Japanese Veterinary Antimicrobial Resistance Monitoring System (JVARM) ............................................... 92
1) Overview ....................................................................................................................................................... 92
2) System for the antimicrobial resistance monitoring ....................................................................................... 92
3) Monitoring on the sales volumes of antimicrobials ....................................................................................... 94
4) Collaboration with JANIS ............................................................................................................................. 95
5) Prospects ........................................................................................................................................................ 96
(6) Japan Antimicrobial Use Surveillance (JAMUS) ............................................................................................ 96
1) Overview ....................................................................................................................................................... 96
2) Monitoring methods ...................................................................................................................................... 96
3) Prospects ........................................................................................................................................................ 97
(7) Monitoring on the antimicrobial-resistant Campylobacter spp. isolated from humans ................................... 97
1) Overview ....................................................................................................................................................... 97
2) Survey methods ............................................................................................................................................. 97
3) Prospects ........................................................................................................................................................ 97
(8) Monitoring on the antimicrobial-resistant non-typhoidal Salmonella spp. isolated from humans and from
food ....................................................................................................................................................................... 97
1) Overview ....................................................................................................................................................... 97
2) Methods ......................................................................................................................................................... 97
3) Prospects ........................................................................................................................................................ 98
2
(2) Surveys of healthcare providers ...................................................................................................................... 84
1) Survey of attitudes among pharmacists at health insurance pharmacies ........................................................ 84
2) Survey of attitudes among undergraduate medical students .......................................................................... 85
(3) Survey of veterinary science students ............................................................................................................. 85
Way Forward ............................................................................................................................ 87
Appendix ................................................................................................................................................ 88
(1) Japan Nosocomial Infections Surveillance (JANIS) ....................................................................................... 88
1) Overview ....................................................................................................................................................... 88
2) Methods for submission................................................................................................................................. 88
3) Prospects ........................................................................................................................................................ 88
(2) National Epidemiological Surveillance of Infectious Disease (NESID) ......................................................... 89
1) Overview ....................................................................................................................................................... 89
2) Reporting criteria ........................................................................................................................................... 89
3) System ........................................................................................................................................................... 90
4) Prospects ........................................................................................................................................................ 90
(3) Japan Surveillance for Infection Prevention and Health‐care Epidemiology (J-SIPHE)................................. 91
1) Overview ....................................................................................................................................................... 91
2) System ........................................................................................................................................................... 91
3) Prospects ........................................................................................................................................................ 91
(4) Trend surveillance of antimicrobial-resistant Mycobacterium tuberculosis .................................................... 91
1) Overview ....................................................................................................................................................... 91
2) Survey methods ............................................................................................................................................. 91
3) System ........................................................................................................................................................... 91
4) Prospects ........................................................................................................................................................ 91
(5) Japanese Veterinary Antimicrobial Resistance Monitoring System (JVARM) ............................................... 92
1) Overview ....................................................................................................................................................... 92
2) System for the antimicrobial resistance monitoring ....................................................................................... 92
3) Monitoring on the sales volumes of antimicrobials ....................................................................................... 94
4) Collaboration with JANIS ............................................................................................................................. 95
5) Prospects ........................................................................................................................................................ 96
(6) Japan Antimicrobial Use Surveillance (JAMUS) ............................................................................................ 96
1) Overview ....................................................................................................................................................... 96
2) Monitoring methods ...................................................................................................................................... 96
3) Prospects ........................................................................................................................................................ 97
(7) Monitoring on the antimicrobial-resistant Campylobacter spp. isolated from humans ................................... 97
1) Overview ....................................................................................................................................................... 97
2) Survey methods ............................................................................................................................................. 97
3) Prospects ........................................................................................................................................................ 97
(8) Monitoring on the antimicrobial-resistant non-typhoidal Salmonella spp. isolated from humans and from
food ....................................................................................................................................................................... 97
1) Overview ....................................................................................................................................................... 97
2) Methods ......................................................................................................................................................... 97
3) Prospects ........................................................................................................................................................ 98
2